Novavax offers first evidence that COVID vaccines protect people against variants
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Novavax and Johnson & Johnson vaccines showed a substantial drop in efficacy in South Africa.
“both the Novavax and Johnson & Johnson vaccines showed a substantial drop in efficacy in South Africa 37,38”
From Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 (2021) · cites this paper as [38]
Preliminary information suggests a vaccine based on the S protein might provide less effective protection in South Africa compared to the United States.
“Such a scenario would be in keeping with preliminary information suggesting that a vaccine based on the S protein might provide less effective protection in South Africa as compared to the United States (Callaway and Mallapaty, 2021).”
From SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021) · cites this paper as Callaway and Mallapaty, 2021
The citation lists haven’t been fetched yet
Cited by 107
- Authors
- Callaway, E., & Mallapaty, S.
- Venue
- Nature
- Published
- 2021-01-29
- Volume
- 590
- Issue
- 7844
- Pages
- 17-17
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3125936678
- Cited by
- 107
- References
- 0
- Citations by year
- 2025: 3 · 2024: 9 · 2023: 7 · 2022: 33 · 2021: 55
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- Novavax, COVID-19 vaccines, vaccine efficacy, SARS-CoV-2 variants, B.1.1.7 variant, B.1.351 variant
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Biotechnology, Clinical Trials as Topic, Drug Industry, United Kingdom, Humans, Immunization, Secondary, South Africa, Genetic Variation, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
